Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Strategic Projects - Group

Ryerson University

$166,367.00

Microfluidic manufacturing of uniform nano and microbubbles for ultrasound based imaging and therapeutics**applications

EF 2018-19

Résumé
This NSERC Strategic Projects grant is funding the development of a microfluidics-based manufacturing technology that achieves uniform size and high-throughput production of nano and microbubbles in the diameter range of 50 nm - 10 µm. (We simply refer to these bubbles as microbubbles.) The strategy we employ achieves highly uniform microbubbles that overcome the large size distribution limitations of existing commercially available microbubbles that are used as clinical ultrasound contrast agents and also increasingly as therapeutic delivery agents. Specifically, despite the significant potential utility of microbubbles in ultrasound imaging and therapeutics, commercially available microbubbles have a large distribution of sizes, which result in sub-optimal imaging conditions and therapeutic effects. Our advanced manufacturing approach overcomes these issues by enabling precise user-control of microbubble sizes. One key novelty of our technique is the application of vacuum-shrinkage of microbubbles after the bubbles are generated microfluidically. Our goals in this Project are to 1) model and achieve precise control of bubble sizes from 50 nm - 10 µm, 2) scale-up the production of the microbubbles to clinically relevant levels by integrating an edge emulsification microfluidic microbubble generation scheme to our manufacturing technology, and 3) embed in-line quality control of the microbubbles by ultrasound inspection. *The microbubbles we are making are safe: commercially available microbubbles have been approved for clinical use in many countries, including in Canada and the United States. The microbubble ultrasound contrast agents also have a growing global market, from $4.46B USD in 2016 to a projected $5.44B USD in 2021 at a compounded annual growth rate (CAGR) of 4.1%. Thus, we anticipate that the development of our technology will help the Canadian micro and nanotechnology manufacturing industry gain access into this potentially highly lucrative market, and improve Canada's employment in the manufacturing technology sector.*
Programme
Strategic Projects - Group
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
506318-2017
Name nom
Tsai, Scott
Department département
Mechanical and Industrial Engineering
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
166367
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1586
Committee name en
Strategic Projects - Advanced Manufacturing
Committee name fr
Projets stratégiques - Fabrication de pointe
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
2100
Research subject group en
Mechanical engineering
Research subject group fr
Génie mécanique
Research subject en
Mechanical engineering
Research subject fr
Génie mécanique
Partie
2
Nb partie
2
Application title
Microfluidic manufacturing of uniform nano and microbubbles for ultrasound based imaging and therapeutics**applications
Keyword
NSERC
Application summary
This NSERC Strategic Projects grant is funding the development of a microfluidics-based manufacturing technology that achieves uniform size and high-throughput production of nano and microbubbles in the diameter range of 50 nm - 10 µm. (We simply refer to these bubbles as microbubbles.) The strategy we employ achieves highly uniform microbubbles that overcome the large size distribution limitations of existing commercially available microbubbles that are used as clinical ultrasound contrast agents and also increasingly as therapeutic delivery agents. Specifically, despite the significant potential utility of microbubbles in ultrasound imaging and therapeutics, commercially available microbubbles have a large distribution of sizes, which result in sub-optimal imaging conditions and therapeutic effects. Our advanced manufacturing approach overcomes these issues by enabling precise user-control of microbubble sizes. One key novelty of our technique is the application of vacuum-shrinkage of microbubbles after the bubbles are generated microfluidically. Our goals in this Project are to 1) model and achieve precise control of bubble sizes from 50 nm - 10 µm, 2) scale-up the production of the microbubbles to clinically relevant levels by integrating an edge emulsification microfluidic microbubble generation scheme to our manufacturing technology, and 3) embed in-line quality control of the microbubbles by ultrasound inspection. *The microbubbles we are making are safe: commercially available microbubbles have been approved for clinical use in many countries, including in Canada and the United States. The microbubble ultrasound contrast agents also have a growing global market, from $4.46B USD in 2016 to a projected $5.44B USD in 2021 at a compounded annual growth rate (CAGR) of 4.1%. Thus, we anticipate that the development of our technology will help the Canadian micro and nanotechnology manufacturing industry gain access into this potentially highly lucrative market, and improve Canada's employment in the manufacturing technology sector.*